20107 results for «»
20107 results
Complex mitral and tricuspid TEER
16 Nov 2025 – From PCR London Valves 2025
This session highlights complex cases in mitral and tricuspid transcatheter edge-to-edge repair (TEER), addressing challenges such as septal obstacles in patients with old atrial septal occluders, management of residual atrial septal defects post-mitral valve-in-ring replacement, and innovative multidisciplinary approaches. It also covers hybrid transapical mitral valve-in-valve...
From clinical benefits to cost effectiveness: impact of early intervention in asymptomatic severe AS
16 Nov 2025 – From PCR London Valves 2025
Francesco Saia discusses the clinical benefits of early intervention in asymptomatic severe aortic stenosis with Philippe Généreux and Tiffany Patterson. EARLY TAVR trial and supporting studies showed a reduction in death, stroke, and heart failure compared with surveillance. Economic modelling shows early intervention is cost-effective and...
ENCIRCLE 1-year outcomes: Shaping the future of MR treatment with the SAPIEN M3 system
18 Nov 2025 – From PCR London Valves 2025
Fabien Praz talks with Mayra Guerrero and Henryk Dreger about the ENCIRCLE trial on the Sapien M3 transcatheter mitral valve, which shows strong safety, durable MR reduction, and improved symptoms, quality of life, and LV remodelling. High-quality CT and echo are essential for #TMVR, which is...
Retrieval of embolised devices
16 Nov 2025 – From PCR London Valves 2025
This session delves into the complex scenarios of embolised device retrieval, exploring various interventions such as management of Lambre device embolisation, alternatives to surgery for superior vena cava baffle stent embolisation, novel strategies for chronically embolised Gore Helex atrial septal occluder device retrieval, and challenging redo...
Five-year outcomes following early experience with transapical TMVR
16 Nov 2025 – From PCR London Valves 2025
In this discussion, Christopher Allen and Michael Reardon review the five-year results of an early transapical TMVR system implanted in very high-risk, inoperable patients.
The device showed sustained elimination of mitral regurgitation, with over 80% of patients maintaining trace or no MR at five years and no...
From pivotal trial to real-world impact: shaping TR treatment today with the EVOQUE system
16 Nov 2025 – From PCR London Valves 2025
Rebecca Hahn, Varius Dannenberg and Matti Adam discuss the updated ESC/EACTS guidelines for tricuspid regurgitation, which upgrade transcatheter tricuspid interventions to a IIa recommendation. Evidence from the TRILUMINATE and TRISCEND II trials shows improved quality of life and reduced heart failure hospitalisations, especially in patients with...
Aortic valve: PCR London Valves 2025 highlights
17 Nov 2025 – From PCR London Valves 2025
At PCR London Valves 2025, Chris Cook speaks with Course Directors Bernard Prendergast and Simon Redwood about the main highlights from the aortic track. They underline the growing focus on lifetime management, including valve choice, future coronary access, durability, and new long-term data supporting TAVI in...
Mitral valve: PCR London Valves 2025 highlights
17 Nov 2025 – From PCR London Valves 2025
Together with Chris Allen, Course Directors Tiffany Patterson and Nina Wunderlich highlight the Mitral programme from PCR London Valves 2025. The Course began with fundamentals, including imaging and step-by-step procedural training, and then focused on complex cases, complications, and hands-on discussions. LIVE cases featured edge-to-edge repair,...
Tricuspid valve: PCR London Valves 2025 highlights
18 Nov 2025 – From PCR London Valves 2025
At PCR London Valves 2025, Course Directors Francesco Maisano and Nicolo Piazza highlight with Chris Allen the rapid evolution of tricuspid interventions. They emphasise advances in imaging and simulation, with dedicated labs offering practical multimodality training and hands-on experience. LIVE cases showcased both repair and replacement...
How are the new ESC/EACTS valvular guidelines going to impact my mitral programme?
17 Nov 2025 – From PCR London Valves 2025
Francesco Maisano interviews Michael Borger, co-chair of the 2025 ESC/EACS valvular heart disease guidelines, on their practical impact. The updated guidelines emphasize earlier intervention in primary mitral regurgitation, especially for asymptomatic patients with risk factors, while surgery remains preferred for low-risk patients. Michael Borger stresses the...
How are the new ESC/EACTS valvular guidelines going to impact my tricuspid programme?
17 Nov 2025 – From PCR London Valves 2025
While the PCR London Valves 2025 Course is underway, Francesco Maisano and Fabien Praz discuss how the latest ESC/EACTS valvular guidelines affect clinical practice. What’s changing in surgery? How do repair and replacement strategies differ under the new recommendations, and what’s the impact on transcatheter interventions?...
How to manage current challenges of small aortic annulus?
18 Nov 2025 – From PCR London Valves 2025
Joanna Wykrzykowska and Hélène Eltchaninoff discuss challenges in treating patients with small aortic annuli, which are common, especially in women, and present risks such as higher gradients, coronary occlusion, pacemaker need, and paravalvular leak. Valve selection and positioning are critical, balancing hemodynamics and complication avoidance.
This interview...
Emergency transcatheter valve interventions: alternative therapy or bridge to surgery?
16 Nov 2025 – From PCR London Valves 2025
This session offers a compelling case-based exploration of emergency transcatheter valve interventions, demonstrating their potential as life-saving alternatives or bridges to surgery in high-risk patients. Through detailed clinical scenarios including cardiogenic shock, acute papillary muscle rupture, and severe aortic regurgitation from infective endocarditis, participants gain practical...
Nightmare mitral interventions
16 Nov 2025 – From PCR London Valves 2025
This session presents complex mitral valve intervention cases highlighting procedural challenges and innovative solutions. It includes management of embolised transcatheter mitral valve replacements (TMVR), bailout redo transcatheter edge-to-edge repair (TEER), complications such as acute hypoxia and atrial wall perforations, and the application of TAVI skills in...
Focus on the right ventricle: patient selection and clinical outcomes after tricuspid valve intervention
16 Nov 2025 – From PCR London Valves 2025
Focused on the often-overlooked right ventricle, this session elucidates methods for accurate assessment of right ventricular function prior to transcatheter tricuspid valve interventions. It explores the role of right heart catheterisation in patient selection and timing, and evaluates long-term remodeling patterns post-procedure, providing critical insights for...
Tricuspid valve interventions in complex scenarios
16 Nov 2025 – From PCR London Valves 2025
This session explores tricuspid valve interventions in complex clinical scenarios, emphasizing emerging techniques such as electrosurgical laceration to enable TTVR, emergency TEER for papillary muscle rupture, and expanded options for difficult valve disease. It also addresses procedural challenges when conventional implantation maneuvers fail, transcatheter alternatives for...
Transcatheter solutions for rare complications
16 Nov 2025 – From PCR London Valves 2025
This session focuses on transcatheter solutions for rare and unexpected cardiovascular complications. It features percutaneous closure techniques for ascending aortic pseudoaneurysms, approaches to challenging procedural detachment issues, comprehensive valvular disease management, and complex repairs for coexisting severe aortic coarctation and stenosis, underscoring adaptive interventional strategies for...
Hotline - TAVI - Part 1
16 Nov 2025 – From PCR London Valves 2025
This comprehensive session examines the latest evidence and clinical trial data on TAVI, including comparisons of balloon-expandable versus self-expanding valves in failed bioprostheses, techniques to reduce coronary obstruction risk, and real-world outcomes across diverse populations. Cost-effectiveness analyses and longitudinal studies further inform best practices for optimizing...
Claudia Velazquez Sotelo
Yi-Chun Huang